{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-24-000016","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.220733+00:00","generated_at":"2026-06-05T08:36:00.603188+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Castle Biosciences FY2023 revenue $219.8M (+60%); Q4 $66.1M; guides 2024 $235-240M","bullets":["Full-year 2023 revenue $219.8M (+60% YoY); total test reports 70,429 (+59%). Q4 revenue $66.1M (+72% YoY).","Net loss $57.5M in 2023 vs. $67.1M in 2022; Q4 net loss $2.6M vs. $20.6M. Adjusted EBITDA $(4.4)M year, $9.4M Q4.","Cash, cash equivalents and marketable securities $243.1M at Dec 31, 2023.","TissueCypher test reports +328% YoY; DecisionDx-SCC +92%; IDgenetix +236%.","2024 revenue guidance: $235-240 million; management cites strong commercial momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-24-000016","json":"https://secwatch.observer/filing/0001447362-24-000016.json","markdown":"https://secwatch.observer/filing/0001447362-24-000016.md","text":"https://secwatch.observer/filing/0001447362-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000016/0001447362-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000016/cstl-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:36:00.603188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7eded0b1112f15914c55da2584a4625907528d4c","claim":"CASTLE BIOSCIENCES INC reported the fourth quarter and year ended December 31, 2023 results: revenue $219.8 million, net income $57.5 million.","evidence_excerpt":"in such filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000016/0001447362-24-000016-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$219.8 million"},{"label":"Net income","value":"$57.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}